Caplin Steriles Limited (Caplin), a subsidiary of Caplin Point Laboratories Limited, has secured significant approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Ephedrine Sulfate Injection USP, 50 mg/mL Single Dose Vial. This generic version is therapeutically equivalent to the reference-listed drug (RLD) AKOVAZ, manufactured by Exela Pharma Sciences LLC.
This USFDA approval marks another milestone for Caplin Steriles’ growing portfolio of injectable and ophthalmic products targeting the lucrative US market. The approved Ephedrine Sulfate injection is indicated for treating clinically important hypotension (low blood pressure) occurring during anaesthesia.
According to IQVIA™ (IMS Health), Ephedrine Sulfate injection USP 50 mg/mL holds substantial market potential in the US, with estimated sales of approximately $36 million for the twelve months ending May 2024. By entering this market with a generic alternative, Caplin Steriles is well-positioned to capture a significant share and contribute to cost-effective treatment options for patients.
This recent approval follows Caplin Steriles’ successful USFDA nod in May 2024 for their Abbreviated New Drug Application (ANDA) for Phenylephrine Hydrochloride Ophthalmic Solution USP 2.5% and 10% (eye drops). This generic equivalent of the RLD from Alcon Research LLC is used for pupil dilation during eye examinations.
Caplin Steriles’ continued focus on obtaining US FDA approvals for its generic injectable and ophthalmic products demonstrates its strategic commitment to expanding its presence in the world’s largest pharmaceutical market. These approvals not only represent significant revenue opportunities but also showcase Caplin Steriles’ robust capabilities in developing high-quality, US-market-compliant products.
Caplin Steriles Limited, a Subsidiary of Caplin Point Laboratories Limited, is a fast growing sterile product manufacturing company that is approved by several regulatory agencies such as US FDA, EU-GMP, ANVISA and INVIMA.
Caplin Point Laboratories Limited is a fast-growing pharmaceutical company with a unique business model that caters predominantly to emerging markets in Latin America and Africa.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.
Published on: Jul 19, 2024, 5:41 PM IST
We're Live on WhatsApp! Join our channel for market insights & updates